06.30.16Back to News

Paradigm and IDB Resources Announce Exclusive PCDx Tumor Profiling Service Agreement


Expands Global Distribution Of Cancer Testing Service to Southeast Asia

[PHOENIX, AZ and PETALING JAYA, MALAYSIA, June 30, 2016]– Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing tumor analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with IDB Resources to enable patient access to its cancer profiling service, PCDx, in Malaysia, Brunei & Singapore.

“We are excited to continue expansion of Paradigm’s testing services outside the US,” said David Mallery, President, Paradigm. “IDB Resources provides us with an experienced team to help realize growth in these markets over the short term.”

“We are very pleased to bring cutting-edge oncology services to Southeast Asia that enhance the quality of care for patients battling cancer by providing the oncologists added armamentarium to deliver best-possible care to their patients”, said Tham Kong Weng, Value Partner, IDB Resources.

PCDx is a comprehensive clinical-grade NGS-based test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a tumors DNA, RNA & Protein. The test interrogates the most relevant genomic targets at over 5,000x average depth of coverage with 72 therapeutic associations. Results are typically delivered in 4-5 business days.


Paradigm is a molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit http://www.paradigmdx.com or visit us on Twitter @Paradigm_DX


IDB Resources provides services to the healthcare industry in Malaysia, Brunei and Singapore, with focus on bringing innovation to the medical profession and the patient in this region. Based in Malaysia, the company has strong experience in distribution of medical solutions, including targeted oncology treatment approaches through its network in these markets.


Start getting better results, faster.

Order PCDx